Designing comparative effectiveness research on prescription drugs: Lessons from the clinical trial literature

Health Affairs

Volumn 29, Issue 10, 2010, Pages 1842-1848

  Chokshi, Dave A ^a   Avorn, Jerry ^a,b   Kesselheim, Aaron S ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG;

ARTICLE; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; LITERATURE; METHODOLOGY; ORGANIZATION AND MANAGEMENT; UNITED STATES;

CLINICAL TRIALS AS TOPIC; COMPARATIVE EFFECTIVENESS RESEARCH; PRESCRIPTION DRUGS; RESEARCH DESIGN; REVIEW LITERATURE AS TOPIC; UNITED STATES;

EID: 79952115940     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2010.0843     Document Type: Article

References (55)

1. Institute of Medicine. Initial national priorities for comparative effectiveness research. Washington (DC): National Academies Press; 2009.
2. Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA. 2009;302(13):1437-43.
3. Hochman M, McCormick D. Characteristics of published comparative effectiveness studies of medications. JAMA. 2010;303(10):951-8.
4. US Department of Health and Human Services, Federal Coordinating Council for Comparative Effectiveness Research. Report to the president and the Congress. Washington (DC): HHS; 2009.
5. Sox HC, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med. 2009;151(3):203-5.
6. To access the Appendix, click on the Appendix link in the box to the right of the article online.
7. Joint National Committee. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda (MD): National Heart, Lung, and Blood Institute; 1997.
8. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998;279(23):1903-7.
9. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005;366(9489):895-906.
10. Psaty BM, Weiss NS, Furberg CD. Recent trials in hypertension: compelling science or commercial speech? JAMA. 2006;295(14): 1704-6.
11. Kelley C, Helfand M, Good C, Ganz M. Drug class review: hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins).Washington (DC): VHA Pharmacy Benefits Management Strategic Healthcare Group and Medical Advisory Panel; 2006.
12. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Longterm (MEDAL) programme. Lancet. 2006;368(9549):1771-81.
13. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006; 296(13):1633-44.
14. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional nonsteroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553): 1302-8.
15. Avorn J. Keeping science on top in drug evaluation. N Engl J Med. 2007;357(7):633-5.
16. Food and Drug Administration, Center for Drug Evaluation and Re-search. Joint meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Volume III. Washington (DC): FDA; 2005.
17. Food and Drug Administration, Center for Drug Evaluation and Research. Transcript of Arthritis Advisory Committee Meeting. Washington (DC): FDA; 2007 Apr 12.
18. Colatsky TJ. Reassessing the validity of surrogate markers of drug efficacy in the treatment of coronary artery disease. Curr Opin Investig Drugs. 2009;10(3):239-44.
19. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14): 977-86.
20. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125-35.
21. Marciniak TA. FDA memorandum: cardiovascular events in RECORD, NDA 21-071/S-035 [Internet]. Rockville (MD): Food and Drug Administration; 2010 Jun 14 [cited 2010 Sep 13]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM218493.pdf
22. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-71.
23. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21): 2109-22.
24. Psaty BM, Lumley T. Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs. JAMA. 2008; 299(12):1474-6.
25. Naik AD, Petersen LA. The neglected purpose of comparative-effectiveness research. N Engl J Med. 2009; 360(19):1929-31.
26. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10): 709-17.
27. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543-51.
28. Siu LL. Clinical trials in the elderly-a concept comes of age. N Engl J Med. 2007;356(15):1575-6.
29. Jagsi R, Motomura AR, Amarnath S, Jankovic A, Sheets N, Ubel PA. Under-representation of women in high-impact published clinical cancer research. Cancer. 2009; 115(14):3293-301.
30. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290(12): 1624-32.
31. Center for Medicine in the Public Interest. ALLHAT and CATIE reconsidered: reflections on big studies and evidence based medicine as the measure of comparative effectiveness. New York (NY): The Center; 2007.
32. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-97.
33. Julius S. The ALLHAT study: if you believe in evidence-based medicine, stick to it! J Hypertension. 2003; 21:453-4.
34. Salvetti A, Ghiadoni L. Guidelines for antihypertensive treatment: an update after the ALLHAT study. J Am Soc Nephrol. 2004;15:S51-4.
35. Pollack A. The minimal impact of a big hypertension study. New York Times. 2008 Nov 27:B1.
36. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-23.
37. Wang PS, Ulbricht CM, Schoenbaum M. Improving mental health treatments through comparative effectiveness research. Health Aff (Millwood). 2009;28(3):783-91.
38. Duckworth K, Fitzpatrick MJ. NAMI perspective on CATIE: policy and research implications. Psychiatr Serv. 2008;59(5):537-9.
39. Harris G. Drug makers are advocacy group's biggest donors. New York Times. 2009 Oct 21:A23.
40. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, et al. A randomized trial comparing lungvolume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003; 348(21):2059-73.
41. Carino T, Sheingold S, Tunis S. Using clinical trials as a condition of coverage: lessons from the National Emphysema Treatment Trial. Clin Trials. 2004;1(1):108-21.
42. Kolata G. Medicare says it will pay, but patients say "no thanks." New York Times. 2006 Mar 3.
43. Dreyer NA, Tunis SR, Berger M, Ollendorf D, Mattox P, Gliklich R. Why observational studies should be among the tools used in comparative effectiveness research. Health Aff (Millwood). 2010;29(10):1818-25.
44. Fleurence R, Naci H, Jansen JP. The critical role of observational evidence in comparative effectiveness research. Health Aff (Millwood). 2010;29(10):1826-33
45. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231-42.
46. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243-52.
47. Nelson NJ. Adaptive clinical trial design: has its time come? JNCI. 2010. Epub ahead of print.
48. Luce BR, Kramer JM, Goodman SN, Connor J, Tunis S, Whicher D, et al. Rethinking randomized clinical trials for comparative effectiveness research. Ann Intern Med. 2009;151: 206-9.
49. Congressional Budget Office. Research on the comparative effectiveness of medical treatments. Washington (DC): CBO; 2007.
50. Avorn J. In defense of pharmacoepidemiology-embracing the yin and yang of drug research. N Engl J Med. 2007;357(22):2219-21.
51. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med. 2002;21(16):2313-24.
52. Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease. Lancet. 2009;373(9670):1190-7.
53. Kramer BS, Wilentz J, Alexander D, Burklow J, Friedman LM, Hodes R, et al. Getting it right: being smarter about clinical trials. PLoS Med. 2006;3(6):e144.
54. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;35814:1431-43.
55. Brown BG, Taylor AJ. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med. 2008;358(14):1504-7.